Food-grade encapsulation technology to enhance green tea catechin bioavailability for fetal down syndrome prevention

Overview

This research addresses a critical challenge in prenatal nutrition by developing a food-grade encapsulation strategy to enhance the bioavailability of epigallocatechin gallate (EGCG), the primary catechin in green tea. EGCG is a known inhibitor of DYRK1A kinase, a major contributor to Down syndrome, and has shown promise in mouse models and clinical studies for improving cognitive outcomes. However, its low stability, poor permeability, and active efflux effects limit its therapeutic potential. By encapsulating EGCG using food-grade proteins and polysaccharides, this technology aims to create a novel nutritional ingredient that can effectively deliver EGCG to prevent fetal Down syndrome.

Technical specifications

Core approach:

• Food-grade encapsulation using proteins (such as whey protein) and polysaccharides to protect and deliver EGCG
• Nanoemulsion and powder-based encapsulation formats suitable for incorporation into food matrices
• Targeted release mechanisms designed to improve intestinal absorption

Validated encapsulation performance with similar bioactives:

• Curcumin loading capacity increased from 0.11 µg/mL in water to 9.53 mg/mL in nanoemulsions
• Enhanced stability against 4-week storage, 24-hour UV radiation, and pH variations from 3.0 to 7.4
• Significantly improved bioaccessibility and in vitro absorption ratios compared to free curcumin
• Successful incorporation into yogurt without adverse sensory impact

Future validation plans:

• Stability testing under various temperature, light, and humidity conditions
• In vitro gastrointestinal tract bioaccessibility assessment
• Caco-2 cell model testing for intestinal absorption ratios
• Evaluation of EGCG inhibition effect on cellular H2S production in Down syndrome fibroblasts

Technology readiness level

The encapsulation methodology has been validated with curcumin, a bioactive compound sharing similar instability and low bioavailability characteristics with EGCG. The research team has demonstrated successful encapsulation, improved stability, enhanced bioaccessibility, and food matrix integration. The proposed one-year study will adapt and validate this proven approach specifically for EGCG, advancing the technology toward a functional nutritional ingredient for prenatal Down syndrome prevention. The project is currently seeking partnership support for encapsulation formulation development, funding for cellular model studies, and key personnel support.